Sensus Healthcare, Inc. (NASDAQ:SRTS - Get Free Report) Director Eric Sachetta bought 34,697 shares of the company's stock in a transaction that occurred on Monday, August 24th. The shares were purchased at an average cost of $3.25 per share, for a total transaction of $112,765.25. Following the acquisition, the director owned 209,310 shares of the company's stock, valued at $680,257.50. This represents a 19.87% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website.
Sensus Healthcare Stock Performance
Shares of NASDAQ:SRTS opened at $3.36 on Wednesday. The company has a market capitalization of $55.31 million, a PE ratio of -3.57 and a beta of 1.10. The stock has a fifty day moving average of $3.01 and a 200-day moving average of $3.55. Sensus Healthcare, Inc. has a one year low of $2.66 and a one year high of $5.49.
Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.41). Sensus Healthcare had a negative return on equity of 21.57% and a negative net margin of 88.45%.The company had revenue of $2.29 million for the quarter, compared to analyst estimates of $4.60 million.
Institutional Investors Weigh In On Sensus Healthcare
Hedge funds and other institutional investors have recently made changes to their positions in the company. EP Wealth Advisors LLC bought a new stake in shares of Sensus Healthcare in the 2nd quarter valued at approximately $49,000. BlackRock Inc. acquired a new stake in Sensus Healthcare in the second quarter valued at approximately $252,000. Bank of New York Mellon Corp bought a new stake in Sensus Healthcare in the second quarter worth approximately $303,000. North Star Investment Management Corp. bought a new position in shares of Sensus Healthcare during the 1st quarter valued at $500,000. Finally, XTX Topco Ltd acquired a new stake in shares of Sensus Healthcare in the 4th quarter valued at $77,000. 25.30% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of equities analysts recently commented on SRTS shares. Citigroup reaffirmed a "buy" rating on shares of Sensus Healthcare in a research note on Friday, May 8th. Wall Street Zen downgraded Sensus Healthcare from a "sell" rating to a "strong sell" rating in a report on Saturday, May 9th. Weiss Ratings lowered Sensus Healthcare from a "sell (d)" rating to a "sell (d-)" rating in a research report on Tuesday, August 18th. Lake Street Capital decreased their price objective on Sensus Healthcare from $4.50 to $4.00 and set a "buy" rating for the company in a research report on Friday, August 14th. Finally, Alliance Global Partners reiterated a "buy" rating on shares of Sensus Healthcare in a report on Monday, August 17th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $5.83.
Get Our Latest Stock Analysis on Sensus Healthcare
Sensus Healthcare Company Profile
(
Get Free Report)
Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company's SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare's systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.
The company's flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
